


## CAR-T Therapy Market To Grow At Whopping Rate Of 51% With Help Of Increasing Financial Support

The Business Research Company's CAR-T Therapy Market Report - Opportunities And Strategies - Global Forecast To 2030

LONDON, GREATER LONDON, UK, November 24, 2020 / EINPresswire.com/ -- Avail up to 50% off on ALL research reports at: <a href="https://www.thebusinessresearch.company.com/global-market-reports">https://www.thebusinessresearch.company.com/global-market-reports</a>. Offer applies until Dec 31st.



The global <u>CAR-T therapy market</u> is segmented by target antigen into CD19, CD22, others and by application into acute lymphoblastic leukemia, diffuse large b-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma, and others. CAR-T therapy is an immunotherapy used to treat cancer by using the patient's own cells. In this therapy, the white blood cells are infused with chimeric antigen receptor that modifies the T-type of white blood cells to fight against cancer cells.

Companies in the cell therapy market are conducting clinical trials to assess the ability of CAR-T therapy to treat multiple myeloma. Multiple myeloma is a type of white blood cell cancer where the cancer cells accumulate in the bone marrow and surrounds the healthy blood cells. CAR-T therapy is being tested as a treatment for multiple myeloma. CAR-T cells are modified to target the multiple myeloma causing cells to treat the relapsed or refractory multiple myeloma (RRMM). Sorrento Therapeutics, a USA based developer of therapeutic approaches to treat different types of cancer, developed CAR2 anti-CD38 CAR-T cell therapy to treat RRMM. The CAR2 anti-CD38 CAR-T cell therapy is in Phase 1 of its clinical trial with 72 participant recruitments made by the end of 2019. The aim of the clinical trial is to evaluate the efficiency and safety of CAR2 anti-CD38 CAR-T cell therapy. The trial is expected to be completed in 2020.

The global <u>CAR-T therapy market size</u> was worth \$0.61 billion in 2019. It is expected to grow at a whopping compound annual growth rate of 51.10% and reach \$3.18 billion by 2023. The CAR-T cell therapy market is driven by the increasing financial support provided by different

organizations to promote the development and consumption of CAR-T therapy. Government and non-government organizations provide financial support to the companies in CAR-T therapy market for research and development and to the patients for their treatment of acute lymphoblastic leukemia (ALL), positively affecting the market.

Here Is A List Of Similar Reports By The Business Research Company:
Cell Therapy Market Global Report 2020-30: COVID-19 Growth and Change
<a href="https://www.thebusinessresearchcompany.com/report/cell-therapy-market-global-report-2020-30-covid-19-growth-and-change">https://www.thebusinessresearchcompany.com/report/cell-therapy-market-global-report-2020-30-covid-19-growth-and-change</a>

Stem Cell Therapy Market Global Report 2020-30: COVID-19 Growth and Change <a href="https://www.thebusinessresearchcompany.com/report/stem-cell-therapy-market-global-report-2020-30-covid-19-growth-and-change">https://www.thebusinessresearchcompany.com/report/stem-cell-therapy-market-global-report-2020-30-covid-19-growth-and-change</a>

Cell And Gene Therapy Global Market Report 2020-30: COVID-19 Growth And Change <a href="https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-global-market-report-2020-30-covid-19-growth-and-change">https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-global-market-report-2020-30-covid-19-growth-and-change</a>

Interested to know more about <u>The Business Research Company?</u>

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/531374757

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.